comparemela.com

Latest Breaking News On - Polina miklush - Page 1 : comparemela.com

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

/PRNewswire/ CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement.

United statesPaul mckenziePolina miklushGreg healyCenters for diseaseArcturus therapeutics holdings incSeqirus communicationsCsl rd communicationsArcturus therapeuticArcturus therapeuticsOperating officer paulBill mezzanotteChief medical officerDisease controlAccessed decemberGetting your

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

/PRNewswire/ CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement.

United statesPaul mckenziePolina miklushSteve marlowGreg healyJimmy bakerCenters for diseaseArcturus therapeutics holdings incSeqirus communicationsCsl rd communicationsFinancial communicationsOperating officer paulGeneral managerChief medical officerDisease control

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

/PRNewswire/ CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement.

United statesPaul mckenziePolina miklushSteve marlowGreg healyJimmy bakerCenters for diseaseArcturus therapeutics holdings incSeqirus communicationsCsl rd communicationsFinancial communicationsOperating officer paulGeneral managerChief medical officerDisease control

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entere.

United statesPaul mckenziePolina miklushSteve marlowGreg healyJimmy bakerCenters for diseaseArcturus therapeutics holdings incSeqirus communicationsCsl rd communicationsFinancial communicationsOperating officer paulGeneral managerChief medical officerDisease control

CSL Seqirus Announces U S Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. governmen.

United statesHolly springsNorthern territoryNew jerseyNorth carolinaMarc laceyJonathan edelmanPolina miklushCenters for diseaseVaccines clinical developmentUs department of healthHuman servicesBiomedical advanced researchWorld organisation for animal healthAdministration for strategic preparednessDevelopment authority

vimarsana © 2020. All Rights Reserved.